Conduit Pharmaceuticals (NASDAQ:CDT) Issues Quarterly Earnings Results

Conduit Pharmaceuticals (NASDAQ:CDT) posted its earnings results on Friday. The company reported ($20.33) EPS for the quarter, Zacks reports.

Conduit Pharmaceuticals Trading Up 15.9 %

NASDAQ CDT opened at $0.89 on Friday. Conduit Pharmaceuticals has a 52-week low of $0.73 and a 52-week high of $379.00. The firm’s 50 day moving average price is $1.90 and its 200-day moving average price is $7.07.

Conduit Pharmaceuticals Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.